Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
Chevallier P, Robillard N, Ayari S, Guillaume T, Delaunay J, Mechinaud F, Avet-Loiseau H, Mohty M, Harousseau JL, Garand R. Chevallier P, et al. Among authors: garand r. Br J Haematol. 2008 Dec;143(5):744-6. doi: 10.1111/j.1365-2141.2008.07153.x. Br J Haematol. 2008. PMID: 19036018 Free article. No abstract available.
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL. Chevallier P, et al. Among authors: garand r. Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8. Leuk Res. 2005. PMID: 16038726
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Chevallier P, et al. Among authors: garand r. J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.
Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J, Harousseau JL, Avet-Loiseau H, Mohty M, Garand R. Chevallier P, et al. Among authors: garand r. Leukemia. 2009 Apr;23(4):806-7. doi: 10.1038/leu.2008.303. Epub 2008 Oct 30. Leukemia. 2009. PMID: 18971949 No abstract available.
Trisomy 4 associated with acute lymphocytic leukaemia.
Moreau P, Talmant P, Milpied N, Garand R, Lefranc G, Harousseau JL. Moreau P, et al. Among authors: garand r. Br J Haematol. 1991 Aug;78(4):576. doi: 10.1111/j.1365-2141.1991.tb04495.x. Br J Haematol. 1991. PMID: 1911352 No abstract available.
100 results